Market Intelligence, Clinical Progress, and High-Purity Reagents for Neurodegenerative Disease Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for PRNP drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | PRNP ECD-Fc / Mutant Protein High purity (>95%), Endotoxin controlled. Sequence Verified. HEK293 expressed for native glycosylation. |
View PRNP Products |
| Gene Delivery | PRNP Promise-ORF / Lentivirus Full-length ORF for stable cell line construction and expression validation. |
View PRNP Products |
| Benchmark Ab | Anti-PRNP Recombinant Antibody Sequence derived from clinical benchmark (PRN100). Recombinant positive control. |
View PRNP Products |
| Validator | PRNP siRNA Set For knockdown verification in cell-based assays. |
View PRNP Products |
| Related Target A | APP (Amyloid Beta Precursor) PRNP acts as a high-affinity receptor for Amyloid-beta oligomers, mediating synaptic toxicity. |
View APP Products |
| Related Target B | LRP1 (Low-Density Lipoprotein Receptor-Related Protein 1) Co-receptor mediating PRNP endocytosis and signaling pathways. |
View LRP1 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Conformational Stability & Misfolding Analysis | HEK293-expressed recombinant PRNP preserves post-translational modifications (GPI-anchor signal, N-glycans) essential for native folding. |
| Familial Mutation Modeling (e.g., E200K, D178N) | Custom mutant recombinant proteins and lentiviral vectors engineered with precise sequence verification. |
| Lack of Validated Reference Controls | Clinical-grade benchmark antibody (PRN100 sequence) available for assay standardization. |
| Off-Target & Specificity Screening | High-purity sequence-verified homolog panels and validated siRNA knockdown tools. |
Live PRNP R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The therapeutic targeting of the prion protein (PRNP/PrP) is expanding beyond rare transmissible spongiform encephalopathies (TSEs) like Creutzfeldt-Jakob Disease (CJD) into broader neurodegenerative indications, including Alzheimer's disease. The primary clinical focus is shifting from generic clearance mechanisms to precise conformational stabilization of cellular prion protein (PrPC) and targeted expression knockdown. As first-generation antisense oligonucleotides (ASOs) and monoclonal antibodies advance through early-phase trials, the next wave of R&D is heavily focused on brain-penetrant small molecules and blood-brain barrier (BBB)-crossing biologics.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Antisense Oligonucleotides (ASO) | Ionis Pharmaceuticals | Prion Diseases (CJD, FFI) | Target knockdown validation (Need PRNP siRNA controls & Lentivirus for stable cell lines) |
| Monoclonal Antibodies (mAb) | University College London (UCL) / MRC Prion Unit | Creutzfeldt-Jakob Disease | Conformational binding assays (Need native glycosylated PRNP ECD-Fc and PRN100 benchmark) |
| Small Molecule Stabilizers | Broad Institute / Sangamo | Genetic Prion Diseases | Biophysical binding & thermal shift assays (Need high-purity recombinant WT and mutant proteins) |